Sonlicromanol - Khondrion
Alternative Names: KH 176Latest Information Update: 17 Sep 2024
At a glance
- Originator Khondrion
- Class Antiparkinsonians; Benzopyrans; Piperidines; Small molecules
- Mechanism of Action Prostaglandin-E synthase inhibitors; Reactive oxygen species modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Mitochondrial disorders
- No development reported Parkinson's disease
Most Recent Events
- 01 Nov 2023 Khondrion plans a phase III trial in Mitochondrial disorders (PO) in H2 of 2024
- 19 Oct 2023 Khondrion has patent protection for the use of sonlicromanol as an anti inflammatory agent in Europe
- 13 Jun 2023 Khondrion has patent protection for the use of sonlicromanol as an anti inflammatory agent in USA